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Abstract
The metabolic syndrome is thought to be associated with a chronic low-grade inflammation, and a growing body
of evidence suggests that interleukin-18 (IL-18) might be closely related to the metabolic syndrome and its conse-
quences. Circulating levels of IL-18 have been reported to be elevated in subjects with the metabolic syndrome, to
be closely associated with the components of the syndrome, to predict cardiovascular events and mortality in
populations with the metabolic syndrome and to precede the development of type 2 diabetes. IL-18 is found in
the unstable atherosclerotic plaque, in adipose tissue and in muscle tissue, and is subject to several regulatory
steps including cleavage by caspase-1, inactivation by IL-18 binding protein and the influence of other cytokines in
modulating its interaction with the IL-18 receptor. The purpose of this review is to outline the role of IL-18 in the
metabolic syndrome, with particular emphasis on cardiovascular risk and the potential effect of life style
interventions.
Introduction
The metabolic syndrome is a cluster of risk factors that
identifies a population with increased risk for developing
type 2 diabetes mellitus and cardiovascular disease
(CVD). The syndrome has received increased attention
after practical definitions by the Adult Treatment Panel
III and International Diabetes Federation [1,2]. The
diagnostic criteria vary slightly, in particular concerning
the meausure for central obesity, but in a recent state-
ment it is agreed that the presence of any three of the
following five components is diagnostic for the meta-
bolic syndrome: Central obesity, elevated blood pressure,
raised fasting glucose, raised levels of trigycerides and
low levels of high-density lipoprotein cholesterol [3].
More than 25% of the US population can be classified
as having the metabolic syndrome, and the prevalence is
increasing with age, affecting >40% of US adults above
the age of 60 years [4-6].
The metabolic syndrome is a strong predictor of type
2 diabetes, with an increased incidence rate of 5 to
7-fold [7,8]. Indeed, the increased cardiovascular risk
might develop as a continuum in parallel with increasing
fasting glucose, from the normal range via impaired fast-
ing glucose to overt diabetes mellitus [9]. The risk of
developing CVD is approximately doubled in the meta-
bolic syndrome [10]. In a meta-analysis including
43 cohorts, the relative risk for cardiovascular events
and death was 1.78, with the highest risk in women [11].
There is increasing evidence that the metabolic syn-
drome is associated with a chronic, low-grade inflamma-
tion [2]. Several pro-inflammatory cytokines have been
shown to be elevated in parallel with an increasing
number of components of the syndrome, whereas the
anti-inflammatory and adipocyte-specific substance adi-
ponectin is consistently lower [12-15]. Some investiga-
tors have discussed that both type 2 diabetes, metabolic
syndrome and atherosclerosis are multifactorial condi-
tions which appear to have a common inflammatory
basis [16], and it is currently discussed if a measure of
inflammation should be included in the definition of the
syndrome [2,17]. So far, CRP has been the most likely
candidate [17,18].
However, a growing body of evidence suggests that IL-
18 is closely associated with the metabolic syndrome and
its consequences. The purpose of this review is to outline
the role of IL-18 in the metabolic syndrome, with parti-
cular emphasis on CVD risk and life style interventions.
Interleukin-18: a unique proinflammatory cytokine
IL-18 is a member of the IL-1 family of cytokines and
was originally described as an interferon gamma (IFN-g)
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any medium, provided the original work is properly cited.inducing factor [19]. The cytokine is produced constitu-
tively in many different cell types, including macro-
phages, endothelial cells, vascular smooth muscle cells,
dendritic cells and Kupffer cells [20-22]. IL-18 is also
produced in adipocytes [23], but non-adipocyte cells
have been identified as the main source of IL-18 in adi-
pose tissue [24]. In contrast to most other cytokines,
but in a similar way to IL-1b, IL-18 is expressed as a
precursor, pro-IL18, which is inactive until cleaved by
the enzyme caspase-1 [25]. Notably, caspase-1 itself
exists as an inactive precursor which requires the assem-
bly of multi-unit complexes, known as inflammasomes,
to be activated [26,27].
Once secreted, IL-18 is bound and inactivated by IL-
18 binding protein, which is enhanced as a negative
feedback mechanism in response to increased IL-18 pro-
duction, ensuring protection from tissue damage due to
uncontrolled proinflammatory activity [28,29]. IL-18
binds to its receptor, consisting of an a chain which is
responsible for extracellular binding of IL-18, and a b
chain which is responsible for intracellular signal trans-
duction [25,30,31]. Although both free and protein-
bound IL-18 may bind to the a chain, only the free frac-
tion is able to activate the b chain [28,29].
IL-18 is a potent proinflammatory cytokine which
enhances T cell and natural killer cell maturation, as
well as the production of cytokines, chemokines and cell
adhesion molecules [32,33]. Of note, in CD4+ lympho-
cytes IL-18 can stimulate both type 1 helper T (Th1)
and Th2 responses depending on its cytokine milieu: IL-
18 may stimulate a Th2 response in combination with
IL-2, and may act synergistically with IL-12 to stimulate
a Th1 response with production of IFN-g [25], a central
feature in the atherosclerotic lesion (Figure 1). One
mechanism underlying this synergistic effect is that IL-
12 may induce the a chain of the IL-18 receptor in lym-
phocytes [34,35], whereas in non-T cells such as macro-
phages, the IL-18 receptor is constitutively expressed.
Interleukin-18 in the metabolic syndrome and type 2
diabetes
IL-18 has in several studies been associated with obesity
[14,36-38], insulin resistance [39-41], hypertension [42]
and dyslipidemia [14,37]. Furthermore, IL-18 has been
shown to be elevated in subjects with the metabolic syn-
drome [43] and to increase in parallell with an increas-
ing number of components of the syndrome [38]. In a
large cross sectional study, elevated IL-18 levels were
associated with increasing number of components also
after adjustment for insulin resistance, obesity, IL-6 and
CRP [14]. Polymorphisms in the IL-18 gene have been
shown to be associated with circulating IL-18 levels
[44]. Interestingly, a recent study showed that one such
polymorphism was associated with increased serum
levels of IL-18, impaired insulin sensitivity and increased
risk of having the metabolic syndrome [45], suggesting
that IL-18 might be involved in the pathogenesis of the
syndrome.
Circulating levels of IL-18 have consistently been
reported to be elevated in patients with type 2 diabetes
mellitus in cross sectional studies [40,46,47], and have
also been suggested to contribute to microangiopathy
such as nephropathy in type 2 diabetes [48]. Moreover,
in two prospective cohorts, elevated levels of IL-18 have
been shown to predict the development of type 2 dia-
betes (Table 1) [49,50]. However, a major limitation of
both studies is that fasting glucose or oral glucose toler-
ance tests were not performed at baseline evaluation:
Elevated fasting glucose increases the risk of diabetes,
and experimental hyperglycemia might increase circulat-
ing levels of IL-18 [51].
Interleukin-18 and cardiovascular disease
Studies regarding assocations between IL-18 and stable
atherosclerosis have yielded conflicting results. One
study showed that elevated levels of IL-18 were asso-
ciated with the presence of subclinical atherosclerosis
evaluated with intima media thickness of the carotid
artery, also after adjustment for traditional risk factors,
CRP and IL-6 [52]. On the other hand, in two large stu-
dies elevated levels of IL-18 were associated with carotid
intima media thickness in univariate analyses, but not
after adjustment for traditional risk factors [38,53].
Furthermore, in a study of patients with type 2 diabetes,
both carotid intima media thickness and brachial-ankle
pulse wave velocity were significantly associated with
serum levels of IL-18, although not in multivariate ana-
lyses [54]. However, we recently showed that arterial
stiffness measured by brachial pulse wave propagation
was associated with IL-18 levels and components of the
metabolic syndrome, even in multivariate analyses, both
cross sectionally and during three years follow up [55].
Also data regarding IL-18 as a potential predictor of
future cardiovascular events have so far been conflicting
(Table 1). In patients with known coronary artery dis-
ease, circulating IL-18 levels as well as polymorphisms
in the IL-18 gene were associated with future cardiovas-
cular mortality [56,57]. In two prospective studies, ele-
vated IL-18 levels were associated with future
cardiovascular disease in previously healthy men [58]
and women [59]. However, another large population
based study with a follow up of 11 years showed that
increased levels of IL-6 and CRP, but not IL-18 were
associated with future coronary events [60]. Further-
more, a recent study from five European prospective
CVD cohorts showed no association between poly-
morphisms in the IL-18 receptor genes and cardiovascu-
lar risk [61].
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IL-18 as a potential predictor of cardiovascular events in
populations with the metabolic syndrome (Table 1). In a
large cohort consisting of men and women with known
coronary artery disease, IL-18 was the only independent
predictor of cardiovascular mortality in a subgroup with
the metabolic syndrome, even after adjustment for CRP,
IL-6 and fibrinogen [62]. In line with these results, we
showed that IL-18 was a strong and independent predic-
tor of cardiovascular events in elderly men with the
metabolic syndrome, also after adjustment for CRP and
IL-6, and with a synergistic effect of IL-18 and fasting
glucose in the cardiovascular risk prediction [63].
Potential mechanisms for interleukin-18 in the metabolic
syndrome and atherosclerosis
Interleukin-18 in atherosclerotic lesions
IL-18 has been shown to be highly expressed in athero-
sclerotic plaques, mainly in plaque macrophages, and in
particular in unstable plaques [64]. IL-18 is thought to
Figure 1 Regulation and biological effects of interleukin-18.T h ec y t o k i n ei se x p r e s s e da sap r e c u r s o r ,p r o - I L - 1 8 ,w h i c hi si n a c t i v eu n t i l
cleaved by caspase-1. Once secreted, IL-18 is bound and inactivated by IL-18 binding protein (IL-18 BP), and only the free fraction can stimulate
a signal transduction via the b-chain of the IL-18 receptor (IL-18R). The biological effect is dependent on the cytokine milieu: IL-18 may stimulate
a Th2 response in combination with IL-2, and may act synergistically with IL-12 to stimulate a Th1 response with production of IFN-g, a central
feature of the atherosclerotic lesion.
Table 1 Prospective studies evaluating the effect of elevated circulating IL-18 levels on cardiovascular, metabolic
syndrome and diabetes related end points.
Study Patients (n) and study population Follow-up,
years
End points Outcome
Blankenberg et al. [56] 1229
(known CAD)
4 Cardiovascular
mortality
Increased risk of cardiovascular
mortality
Blankenberg et al. [58] 335 cases and 670 controls
(healthy men)
5 CAD Increased risk of CAD
Everett et al. [59] 253 cases and 253 controls
(healthy women)
6 CVD Increased risk of CVD
Koenig et al. [60] 382 cases and 1980 controls
(population based)
11 CAD No increased risk of CAD
Espinola-Klein et al. [62] 1263, stratified for MS
(known CAD)
6 Cardiovascular
mortality
Increased risk of cardiovascular
mortality in MS strata
Trøseid et al. [63] 563, stratified for MS (elderly high
risk men)
3 CVD Increased risk of CVD in MS strata
Thorand et al. [50] 527 cases and 1698 controls
(population based)
11 Type 2 diabetes Increased risk of type 2 diabetes
Hivert et al. [49] 1012 cases and 1081 controls
(women)
12 Type 2 diabetes Increased risk of type 2 diabetes
CAD; coronary artery disease, CVD; cardiovascular disease, MS; metabolic syndrome.
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production, which potentiates the inflammatory process
and may lead to thinning or inhibition of the fibrous
cap formation, resulting in vulnerable, rupture-prone
plaques [65,66]. Furthermore, IL-18 seems to increase
the expression of matrix metalloproteinases in vascular
cells and macrophages, which might also contribute to
plaque destabilisation [22,65].
Indeed, IL-18 might also directly cause plaque destabi-
lisation and cardiac dysfunction. In a model with Apo E
deficient mice, IL-18 overexpression enhanced the col-
lagenolytic activity of smooth muscle cells, reduced inti-
mal collagen content and fibrous cap thickness, leading
to vulnerable plaque morphology [67]. Furthermore, in a
mouse model with myocardial infarction, increased
expression of cardiac IL-18 mRNA and a subsequent
reduction of myocardial contractility were reported [68].
Interestingly, in a rat model with the metabolic syn-
drome, IL-18 overexpression aggravated insulin resis-
tance, increased vascular inflammation and promoted
remodeling by enhanced infiltration of macrophages and
increased medial thickness in the aortic wall [69].
Interleukin-18 in adipose tissue
The classical perception of adipose tissue as a passive
storage place of fatty acids has gradually been replaced
by the notion of adipose tissue, and visceral fat in parti-
cular as an active endocrine organ. Visceral fat is now
considered a central feature and potential cause of the
metabolic syndrome [70], in part mediated by release of
a large number of metabolically active substances
known as adipokines. Adipokines are involved in several
biological processes, including inflammation, thrombo-
sis, insulin sensitivity and energy balance [71].
Human preadipocytes and adipocytes of all stages have
been shown to spontaneously express and secrete IL-18
[23,72]. Of note, in obese individuals there is an
increased expression of IL-18 in adipose tissue [36], and
a 3-fold increased secretion from adipocytes compared
with lean controls [23]. Interestingly, experimental
hyperglycemia has been shown to increase the expres-
sion of IL-18 in adipocytes, an effect which was even
more pronounced in the presence of intermittent hyper-
glycemia [73]. However, other studies have reported that
non-adipocytes are the main sources of IL-18 in adipose
tissue [24].
Whereas previous studies have reported macrophage
infiltration in adipose tissue in obesity and insulin resis-
tance [74,75], a recent study showed that infiltration of
T-lymphocytes preceded the infiltration of macrophages
in adipose tissue in early stages of insulin resistance in
obese mice [76]. Notably, in human patients with type 2
diabetes from the same report, waist circumference cor-
related significantly with expression of IFN-g in adipose
tissue, suggesting a role of Th1 cells in insulin resistance
[76]. Moreover, in another study of obese mice, there
was a clear bias towards Th1 polarisation of lympho-
cytes in adipose tissue, which was associated with insu-
lin resistance and could be reversed by immunotherapy
[77]. IL-18 acts in synergy with IL-12 to stimulate Th1
polarisation [25], and levels of IL-12 have been reported
to be increased in subjects with type 2 diabetes and by
experimental hyperglycemia [78,79]. Hence, it could be
speculated that IL-18 in combination with a hyperglyce-
mic proinflammatory milieu might trigger Th1 activa-
tion and IFN-g production [63], both in adipose tissue
and in the atherosclerotic plaque.
Interleukin-18 in muscle tissue
Several reports have suggested that adipose tissue might
not be the main source of IL-18 in patients with obesity
and the metabolic syndrome [36,49,80,81]. In one study,
plasma levels of IL-18 were reduced by weight loss,
whereas no effect was seen on adipose tissue expression
of IL-18 [36]. In another study, we showed that the
reduction of IL-18 levels by exercise was significantly
associated with improvement of the metabolic syn-
drome, but not with a reduction in visceral fat [81].
Hence, other body compartments might be involved.
There is increasing evidence that cytokines are
involved in the regulation of skeletal muscle function,
and tumor necrosis factor-a (TNF-a) has been asso-
ciated with muscle catabolism and loss of muscle func-
tion [82]. IL-18 expression has been demonstrated in
human skeletal muscles in a fiber specific way both in
healthy individuals [83] and in patients with myopathy
[67].
Recently, it was shown experimentally that TNF-a
infusion induced reduced glucose uptake and increased
IL-18 expression in human skeletal muscle tissue but
not in adipose tissue, and the authors suggest that adi-
pose tissue is unlikely to be a major source of IL-18
[80]. Still, it remains to demonstrate whether muscle tis-
sue could be a major source of circulating IL-18 in sub-
jects with and without the metabolic syndrome.
Interleukin-18 resistance
Paradoxically, genetically modified mice with IL-18 defi-
ciency have been reported to develop hyperphagia, obe-
sity and insulin resistance, which might be reversed by
recombinant IL-18 administration [84]. Furthermore, it
was shown that patients with obesity and type 2 diabetes
produce significantly less IFN-g in peripheral blood
mononuclear cells in response to IL-18 stimulation
compared to lean controls, most likely due to reduced
expression of the IL-18 receptor b chain, and the
authors have introduced a consept of IL-18 resistance as
a potential explanation of elevated IL-18 levels in such
patients [85]. This observation is supported by several
studies that report defect leucocyte function and
increased susceptibility to infections in patients with
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mine whether this immunological phenomenon trans-
lates into a similar resistance to the metabolic effects of
IL-18 [85], and which organs that might be involved in
such a process.
Interleukin-18 as a potential therapeutic target
Effects of life style interventions
Lifestyle interventions consisting of diet and exercise
have been shown to improve several cardiovascular risk
factors including the metabolic syndrome and to reduce
the risk of developing type 2 diabetes [89,90]. Hence,
current guidelines for management of the metabolic
syndrome highlight the combination of increased physi-
cal activity (at least 30 minutes on most days of the
week) and improved diet (decreased intake of saturated
fat and simple carbohydrates, increased intake of fruits,
vegetables, whole grain and fish) to achieve a sustained
weight loss and reversal of the components of the syn-
drome [2].
Weight loss mediated by calorie-restricted diet inter-
vention was reported to decrease IL-18 levels in obese
women [91]. Furthermore, combined interventions with
diet and exercise have been shown to reduce IL-18
levels in both obese men [36] and women [92]. We have
reported reduced serum levels of IL-18 by Mediterra-
nean-like diet and omega-3 fatty acid supplementation
in a popluation of elderly high-risk men [93]. In a post
hoc analysis from the same trial, the reduction of IL-18
levels was associated with an increased number of meta-
bolic syndrome components that improved during three
years of intervention [55]. Moreover, Mediterranean-like
diet was shown to reduce levels of CRP, IL-6 and IL-18
in a middle-aged population with the metabolic syn-
drome [94].
Aerobic exercise has been reported to reduce levels of
CRP and IL-18 in subjects with type 2 diabetes [95,96].
In another study, aerobic exercise, but not strength
training, reduced circulating levels of CRP, IL-6 and IL-
18 in older subjects [97]. On the other hand, both
endurance training and strength training reduced
plasma levels of IL-18 in a cohort of HIV-infected
patients with lipodystrophy [23,98]. Furthermore, exer-
cise performed on rowing ergometer reduced adipose
tissue expression of IL-18 in obese subjects [99]. More-
over, in a middle aged cohort of men with the metabolic
syndrome, we have reported reduced levels of IL-18
associated with improvement of metabolic syndrome
components by a combined intervention consisting of
aerobic exercise and strength training [81].
Effects of drug therapy
Several drugs are relevant in the management of the
metabolic syndrome, but this review will focus on the
most commonly used first line drugs recommended in
current guidelines [2], i.e. statins and Angiotensin Con-
verting Enzyme (ACE)-inhibitors/Angiotensin II (ATII)
receptor antagonists.
The effects of statin therapy on IL-18 levels have been
conflicting. Some studies have shown reduced circulat-
ing levels of IL-18 in statin treated patients with
hypercholesterolemia [100,101]. Furthermore, we
showed a tendency to additive effect of exercise and pra-
vastatin on serum levels of IL-18 in subjects with the
metabolic syndrome [81]. On the other hand, one study
showed no effect of 20 months treatment with atorvas-
tatin in patients with stable coronary artery disease
[102]. Moreover, statin therapy has consistently been
reported to increase IL-18 in peripheral mononuclear
cells [103-105]. Hence, the effect of statins on IL-18
levels remains elusive.
Although ACE-inhibitors and ATII receptor antago-
nists have been reported to have several anti-inflamma-
tory properties, very few studies have evaluated the
effect of these compounds on IL-18 levels. In experi-
mental studies, ATII has been shown to increase IL-18
expression in vascular smooth muscle cells [106],
whereas ATII receptor antagonists could inhibit aldos-
teron-induced IL-18 expression in cardiomyocytes [107].
However, candesartan treatment had no effect on circu-
lating levels of IL-18 in patients with stable heart failure
[108].
Conclusions and future perspectives
Several lines of evidence support a pivotal role of IL-18
in the pathogenesis of the metabolic syndrome. Impor-
tantly, IL-18 has been shown to be closely associated
with the metabolic syndrome and its components [14],
to predict cardiovascular events and cardiovascular mor-
tality in populations with the metabolic syndrome
[62,63], and to precede the development of diabetes
[49]. Still, the exact role of IL-18 in these conditions
needs to be clarified.
Although life style interventions such as diet and exer-
cise have been shown to reduce levels of IL-18 in popu-
lations with and without the metabolic syndrome, it
remains to demonstrate that such a reduction translates
into reduced incidence of diabetes and cardiovascular
events. Furthermore, the contribution of adipose tissue,
muscle tissue and other organs in regulating circulating
levels of IL-18, as well as the potential role of IL-18
resistance require further investigation.
Since IL-18 is subject to several regulatory steps
including cleavage by caspase-1, inactivation by IL-18
binding protein, and signalling via the b chain of the IL-
18 receptor, it will be crucial to clarify to what extent
circulating levels of total IL-18 relate to the biological
actions of the cytokine. Finally, strategies for blocking
IL-18 activity are currently investigated in various
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failure [109], and could potentially represent future ther-
apeutic tools for the metabolic syndrome and its
consequences.
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